Drug intelligence / Profile preview

TUL011018

Development stage: Unknown
Lead developer: United Lab
Modality: Small Molecules
Administration: Oral, Topical

Overview

TUL011018 is a small molecule Janus kinase 1 (JAK1) inhibitor, initially developed by Zhuhai United Pharmaceutical Co.,Ltd. It demonstrates high potency for JAK1 with an IC50 value of 3 nM and exhibits significant selectivity over JAK2 and TYK2. The drug has shown effective activity in preclinical models of rheumatoid arthritis (RA) and is currently being investigated for its therapeutic potential in atopic dermatitis.

Brand names: TUL01101TUL-01101TUL 01101
Other names: TUL01101 ointmentTUL-01101 ointmentTUL 01101 ointmentcompound 36 (in medicinal chemistry literature)

Targets

TYK2 (Tyrosine kinase 2)JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on TUL011018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TUL011018.

Explore the full profile